Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given an average recommendation of “Buy” by the twelve ratings firms that are currently covering the company,StockRatingsNetwork reports. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares after opening at $8.36 moved to $9.08 on last trade day and at the end of the day closed at $9.04. Company price to sales ratio in past twelve months was calculated as 31.33 and price to cash ratio as 14.22. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) showed a positive weekly performance of 1.46%.
IGI Laboratories, Inc. (NYSEMKT:IG), a New Jersey-based generic topical pharmaceutical company, announced that it has appointed Damian Finio to its Board of Directors. Mr. Finio will serve as the new Chairman of the Company’s Audit Committee. IGI Laboratories, Inc. (NYSEMKT:IG) shares advanced 15.53% in last trading session and ended the day on $4.76. IG return on equity ratio is recorded as -27.30% and its return on assets is -11.40%. IGI Laboratories, Inc. (NYSEMKT:IG) yearly performance is 175.14%.
Repros Therapeutics Inc (NASDAQ:RPRX) has reached the enrollment goal of 120 subjects in the first of two previously announced head-to-head studies comparing Androxal to the leading US testosterone replacement therapy. The two studies were initiated on January 12, 2014. Repros Therapeutics Inc (NASDAQ:RPRX) shares moved up 8.20% in last trading session and was closed at $17.29 while trading in range of $15.90 – $17.33 – Repros Therapeutics Inc (NASDAQ:RPRX) year to date (YTD) performance is -5.52%.
Cytokinetics, Inc. (NASDAQ:CYTK)’s Robert I. Blum, President and Chief Executive Officer, presented at the 13th Annual Needham Healthcare Conference. Cytokinetics, Inc. (NASDAQ:CYTK) weekly performance is 17.01%. On last trading day company shares ended up $10.80. Cytokinetics, Inc. (NASDAQ:CYTK) distance from 50-day simple moving average (SMA50) is 13.37%. Analysts mean target price for the company is $22.71.